CVS Is Reportedly Breaking Itself in Two
Reports say CVS Health is weighing a split that would unwind its landmark Aetna merger, but the structure, timeline, and who absorbs billions in debt remain unanswered questions heading into a critical earnings call.
After the closing bell on November 3, 2026, the Financial Times reported that CVS Health (NYSE:CVS | CVS Price Prediction) plans to split into two publicly traded companies. Its roughly 9,000 drugstores would be spun off, and Aetna and Caremark would stay together.
The Wall Street Journal followed with a version that sets the split for 2028. CVS had not commented publicly as of that night, and the structure and timeline were described as “still in flux and could yet change.”
Shares closed at $91.41, up $2.90 or 3.28%, for a market cap of $116.91 billion. That gain came before the reports. In early after-hours trading, the stock rose as much as 3.7%, but by 7:59 p.m. ET it sat at $89.58, down $1.83 or 2.00%.
A stock trading at about 11 times forward earnings is likely hiding a stronger business inside it, although a breakup that runs into 2028 could bring costs that eat into the reward.
What the Reports Describe
Nothing has been signed or filed. In the Journal‘s account, one company would hold the retail pharmacies and the mail-order pharmacy. The other would hold Aetna, Signify Health, the specialty pharmacy, and CVS Caremark, which is the pharmacy benefit manager (PBM), the middleman that negotiates drug prices for employers and insurers.
One company would keep the CVS Health name, and chief executive David Joyner would lead it. On the August 5, 2026 call, Joyner was still describing a single enterprise: “Our work with GLP-1s is one example of how we can bring our assets together around the consumer need.”
Why the Pieces May Be Worth More Apart
Retail pharmacy is expected to produce about a third of this year’s estimated $417 billion in revenue. Drugstores earn thin margins, and investors tend to value the whole company at the drugstore’s multiple, which hides an insurer and PBM that would otherwise be compared with managed-care peers.
CVS already has scale, because 2025 revenue reached a record $402.1 billion, up 7.8%. A split would reverse the roughly $78 billion Aetna purchase from 2018, which rested on the claim that owning every link would lower costs.
Political Pressure Gives the Split a Defensive Purpose
Lawmakers are paying closer attention to companies that own every step of the drug chain, and Arkansas and Tennessee have passed laws that bar PBMs from owning pharmacies. Moving the drugstores away from Caremark would reduce that exposure.
CVS looked at options that included a breakup in 2024. Joyner became CEO in October 2024, after activist Glenview Capital pushed for the changes that led to Karen Lynch’s exit.
Costs and Questions Still Unanswered
A spinoff could add standalone costs and cut synergies. Caremark is also under pressure, because pharmacy chief Prem Shah said in August that “we’re trending to a retention rate that’s slightly lower than our historical performance.”
Nobody has said how debt would be split, which company would pay the dividend, what separation would cost, or how a standalone drugstore chain would hold up.
What CVS Earnings Could Reveal About the Split
CVS is expected to report third-quarter results before the market opens on November 4, 2026, with its call at 8 a.m. ET. Consensus calls for EPS of $1.65 on revenue of $104.69 billion.
On valuation, CVS trades at a modest multiple. Full-year adjusted EPS guidance of $7.90 to $8.10, plus a 2027 outlook of at least $8.44, supports the current price even if no breakup ever happens.
That makes a split potential upside not reflected in the current price, although Caremark client losses and a 2028 timeline mean that upside is likely years away.
If CVS confirms the split in the November 4 release with a timeline and a debt plan, the case gets stronger. A return toward the $69.51 52-week low would show the market doubts the plan.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.
